Latest Share Chat

Scancell To Undertake Phase II Study Of Cancer Vaccine SCIB1

Fri, 18th Dec 2015 10:49

LONDON (Alliance News) - Scancell Holdings PLC said Friday it will undertake a Phase II clinical study for its lead cancer vaccine SCIB1 for patients with late stage melanoma, expected to start in the second half of 2016.

The trial is expected to run for around 18 months.

The company has formed its core US investigator team to undertake the study, which is intended to enrol around 80 stage 3/4 metastatic melanoma patients.

Shares in Scancell were up 0.3% at 13.66 pence Friday morning.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Related Shares

More News

26 Mar 2024 14:00

Scancell doses first patient in melanoma-focused trials

(Alliance News) - Scancell Holdings PLC announced on Tuesday that the first patient of a new trial cohort has been dosed with its iSCIB1+ therapeutic....

5 Feb 2024 14:09

TRADING UPDATES: Alliance Pharma appoints chair; FireAngel sales down

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported...

30 Jan 2024 13:56

Scancell interim loss narrows amid finance gain on derivative

(Alliance News) - Scancell Holdings PLC on Tuesday reported a narrowed loss as it gained on the revaluation of derivative liability.

17 Jan 2024 14:26

IN BRIEF: Scancell approved by MHRA to add new cohort to Scope trial

Scancell Holdings PLC - Oxford, England-based developer of immunotherapies for treatment of cancer and infectious disease said - Receives approval fro...

19 Dec 2023 13:35

Scancell raises GBP12 million in total from fundraise

(Alliance News) - Scancell Holdings PLC on Tuesday said it has raised GBP11.9 million in total, from an open offer, placing, and subscription of share...